Free Trial

Cardlytics (NASDAQ:CDLX) CEO Sells $76,927.20 in Stock

Cardlytics logo with Business Services background

Key Points

  • Cardlytics CEO Amit Gupta sold 68,685 shares of the company's stock for a total of $76,927.20, resulting in a 12.26% decrease in his ownership position.
  • Following recent trading, Cardlytics shares have seen a price decline, trading at $1.10 with a market cap of $58.56 million.
  • Analysts have lowered their price targets for Cardlytics, with Lake Street Capital decreasing it from $3.00 to $2.50 and Evercore ISI reducing it from $3.00 to $2.00, reflecting a more cautious outlook.
  • Need better tools to track Cardlytics? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CEO Amit Gupta sold 68,685 shares of the business's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $1.12, for a total transaction of $76,927.20. Following the transaction, the chief executive officer directly owned 491,759 shares in the company, valued at $550,770.08. This trade represents a 12.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Amit Gupta also recently made the following trade(s):

  • On Monday, August 18th, Amit Gupta sold 68,260 shares of Cardlytics stock. The stock was sold at an average price of $1.12, for a total transaction of $76,451.20.
  • On Wednesday, July 2nd, Amit Gupta sold 6,725 shares of Cardlytics stock. The stock was sold at an average price of $1.78, for a total transaction of $11,970.50.

Cardlytics Price Performance

Shares of NASDAQ CDLX traded down $0.0250 during midday trading on Tuesday, reaching $1.10. 1,612,532 shares of the company traded hands, compared to its average volume of 2,324,776. The firm has a market cap of $58.56 million, a PE ratio of -0.30 and a beta of 1.26. The stock's 50-day simple moving average is $1.77 and its 200-day simple moving average is $2.00. Cardlytics, Inc. has a 12 month low of $1.0338 and a 12 month high of $5.2450. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.16 and a current ratio of 1.16.

Hedge Funds Weigh In On Cardlytics

Institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC acquired a new position in Cardlytics during the fourth quarter worth approximately $43,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Cardlytics during the second quarter worth approximately $32,000. Post Resch Tallon Group Inc. boosted its holdings in shares of Cardlytics by 100.0% during the second quarter. Post Resch Tallon Group Inc. now owns 20,000 shares of the company's stock worth $33,000 after acquiring an additional 10,000 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Cardlytics by 46.0% during the fourth quarter. Wells Fargo & Company MN now owns 21,106 shares of the company's stock worth $78,000 after acquiring an additional 6,649 shares during the period. Finally, Sand Hill Global Advisors LLC bought a new stake in shares of Cardlytics during the second quarter worth approximately $35,000. Institutional investors and hedge funds own 68.10% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on CDLX shares. Lake Street Capital cut their target price on Cardlytics from $3.00 to $2.50 and set a "hold" rating on the stock in a research note on Thursday, May 8th. Evercore ISI lowered their price target on Cardlytics from $3.00 to $2.00 and set an "in-line" rating for the company in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Cardlytics presently has an average rating of "Moderate Buy" and a consensus target price of $2.25.

Check Out Our Latest Stock Report on Cardlytics

About Cardlytics

(Get Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Articles

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cardlytics Right Now?

Before you consider Cardlytics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.

While Cardlytics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines